– UK, Nottingham – Scancell Holdings plc (LON: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announced the appointment of Dr. Jean-Michel Cosséry to its Board as Non-Executive Chairman with immediate effect, succeeding Dr. John Chiplin who is stepping down the Board.
Prof Lindy Durrant, CEO said: “I speak on the behalf of all of Scancell that we are excited to welcome Jean-Michel and to capitalise on his experience as we continue on our journey to deliver the next stage of growth. I am deeply indebted to John Chiplin for his hard work, support and boundless enthusiasm over the last 7 years which has allowed us to build the Company into the strong business it is today.”
About Dr. Jean-Michel Cosséry
Dr. Jean-Michel Cosséry brings to Scancell over 25 years of experience in the pharmaceutical and biotechnology industries and a sustained global track record of success in commercial operations as well as in capital raising, US and European public offerings, business development and M&A. Jean-Michel was VP for North America Oncology at Eli Lilly, with responsibility for commercialisation of the company’s oncology portfolio. Preceding this US-based position, he was VP and MD of the Eli Lilly’s European Northern Hub, where he was Chair of the Eli Lilly UK Board and a member of Lilly European Executive Committee. Prior to this Jean-Michel served as VP and CMO at GE Healthcare’s Global Headquarters.
Following his retirement from Eli Lilly in 2018, Jean-Michel has served on the board of Kymab until their acquisition by Sanofi. He was also a member of the Immunocore board prior to the company’s Nasdaq listing. Jean-Michel currently serves on the boards of Malin PLC, Exact Therapeutics AS, Eracal Therapeutics and Sophia Genetics SA. He has also been Chair of The American Pharmaceutical Group in the UK, as well as a board member of the Association of British Pharmaceutical Industry. Jean-Michel holds an MBA from the Rotterdam School of Management (Erasmus University), The Netherlands, as well as a PharmD and a PhD in Nuclear Chemistry and Neurobiology from University Paris, France.
Dr Jean-Michel Cosséry said: “I am delighted to be joining the Scancell team at this pivotal time in the Company’s evolution and to build on the rich history it has in developing four innovate platforms. I am excited about the clinical trials in progress and the life changing improvement these important novel cancer therapies can bring to patients, while enhancing shareholder value. I look forward to working with the Board and the Senior Management Team as we seek to advance Scancell’s strategy.”
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs. The Company’s unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids or enhances the potency of antibodies and their ability to directly kill tumour cells.
For more information : https://www.scancell.co.uk
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.